Noninvasive neuromodulation Evren Technologies specializes in noninvasive vagus nerve stimulation for PTSD and related conditions, presenting a potential market for medical device partnerships, research collaborations, and expanded clinical use cases with healthcare providers and veterans health programs.

Clinical advisory growth Recent appointments to scientific advisory roles (Dr. Laura Rice and Dr. Christopher Batich) signal stronger clinical credibility and opportunities to co develop studies, seek grant funding, and accelerate adoption through key opinion leader engagement.

TA/VNS research tools Phoenix 100 taVNS research system positions Evren as a supplier of advanced research hardware, creating sales leads in academic labs, contract research organizations, and neurostimulation research centers seeking reliable TA/VNS instrumentation.

Reg CF fundraising history Past capital-raise activity on StartEngine indicates investor interest and potential for future funding rounds or collaborations with investors looking to back neurostimulation and PTSD treatment tech.

Mid-market focus With a staff size of 11–50 and revenue in the low millions, Evren sits among smaller medtech players that can be pursued for strategic partnerships, pilot programs, and faster decision cycles compared to larger incumbents.